Literature DB >> 11955631

Functional analysis of the 5'-flanking region of the human alanine:glyoxylate aminotransferase gene AGXT.

Manabu Sato1, Shigenobu Toné, Tetsuya Ishikawa, P Edward Purdue, Christopher J Danpure, Yohsuke Minatogawa.   

Abstract

Primer extension of human liver poly(A)(+) RNA revealed that the main transcription start site of the human alanine:glyoxylate aminotransferase gene (AGXT) is situated near 45 bp upstream from the translation start site. Deletion analysis using the 1203 bp 5'-flanking region of the AGXT gene and a luciferase reporter suggested that the promoter sequence is most likely located 2-325 bp upstream from the translation start site, possibly with enhancer elements 440-700 bp upstream. It was also suggested that the region -2 to -64 is important for the expression of the AGXT gene. The region -2 to -325 has two TATA boxes and some initiator elements.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11955631     DOI: 10.1016/s0167-4781(01)00285-8

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  3 in total

1.  Cellular transfection to deliver alanine-glyoxylate aminotransferase to hepatocytes: a rational gene therapy for primary hyperoxaluria-1 (PH-1).

Authors:  Sweaty Koul; Thomas Johnson; Saroj Pramanik; Hari Koul
Journal:  Am J Nephrol       Date:  2005-04-21       Impact factor: 3.754

2.  Updated genetic testing of Italian patients referred with a clinical diagnosis of primary hyperoxaluria.

Authors:  Alessandra Pelle; Alessandra Cuccurullo; Cecilia Mancini; Regina Sebastiano; Giovanni Stallone; Susanna Negrisolo; Elisa Benetti; Licia Peruzzi; Michele Petrarulo; Mario De Marchi; Martino Marangella; Antonio Amoroso; Daniela Giachino; Giorgia Mandrile
Journal:  J Nephrol       Date:  2016-03-05       Impact factor: 3.902

3.  Molecular requirements for peroxisomal targeting of alanine-glyoxylate aminotransferase as an essential determinant in primary hyperoxaluria type 1.

Authors:  Krisztián Fodor; Janina Wolf; Ralf Erdmann; Wolfgang Schliebs; Matthias Wilmanns
Journal:  PLoS Biol       Date:  2012-04-17       Impact factor: 8.029

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.